Usefulness of Therapeutic Drug Monitoring to Manage Clindamycin-Rifampicin Interaction in a Patient with Diabetic Foot Osteomyelitis
Ther Drug Monit
.
2023 Oct 1;45(5):703-706.
doi: 10.1097/FTD.0000000000001123.
Epub 2023 Aug 1.
Authors
Sophie Magréault
1
,
Judith Charbit
2
,
Narimane Berkane
2
,
Françoise Jaureguy
3
,
Etienne Carbonnelle
3
,
Emmanuel Cosson
2
,
Vincent Jullien
4
,
Hélène Bihan
2
Affiliations
1
Department of Pharmacology, AP-HP, Jean Verdier Hospital, Sorbonne Paris Nord and Sorbonne Paris Cité University, IAME, Bobigny, France.
2
Department of Endocrinology-Diabetology-Nutrition, CRNH-IdF, CINFO, AP-HP, Avicenne Hospital, Sorbonne Paris Cité University, Bobigny, France.
3
Department of Clinical Microbiology, AP-HP, Avicenne Hospital, Sorbonne Paris Nord and Sorbonne Paris Cité University, IAME, Bobigny, France; and.
4
Department of Pharmacology, AP-HP, Jean Verdier Hospital, Sorbonne Paris Nord University, Bobigny, France.
PMID:
37559218
DOI:
10.1097/FTD.0000000000001123
No abstract available
MeSH terms
Clindamycin / therapeutic use
Diabetes Mellitus*
Diabetic Foot* / drug therapy
Drug Monitoring
Humans
Osteomyelitis* / drug therapy
Rifampin / therapeutic use
Substances
Clindamycin
Rifampin